A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials

William Vaughn McCall, Ralph D'Agostino, Aaron Dunn

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objectives: The effects associated with placebo (EAP) have been incompletely described in clinical trials of insomnia treatment. We conducted a meta-analysis of insomnia medication trials for the purpose of estimating the magnitude of sleep EAP. Method: We reviewed Medline for 1966 through 2000 for the meta-analysis. The subject heading of insomnia restricted to the subheading of drug therapy was crossed against the results of a search on the subjects heading placebo and text word placebo. We selected only papers that examined primary insomnia, incorporating both placebo and active medication therapies in a randomized, double-blind, parallel-group design. We required that results be reported for 1, 2, 3, or 4 weeks of treatment, and that outcomes be reported in hours/minutes. Results: Five papers satisfied our requirements for eligibility, comprising 213 patients receiving placebo for a 2-week interval. Subjective sleep latency demonstrated a significant reduction (mean ± S.E.) of 13.1 ± 2.0 min (95% confidence interval (CI) 9.2, 17.0) for the placebo group after combining the data across studies. Subjective total sleep time demonstrated a significant increase of 13.5 ± 5.4 min (95% CI 2.9, 24.0). Polysomnographic (PSG) sleep latency demonstrated a non-significant reduction of 2.5 ± 4.3 min (95% CI -5.9, 10.9). Conclusions: The confirmation of EAP in insomnia clinical trials argues for the retention of a placebo control in future insomnia clinical trials.

Original languageEnglish (US)
Pages (from-to)57-62
Number of pages6
JournalSleep Medicine
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Hypnotics and Sedatives
Meta-Analysis
Sleep
Placebos
Clinical Trials
Sleep Initiation and Maintenance Disorders
Confidence Intervals
Drug Therapy
Therapeutics

Keywords

  • Ethics
  • Hypnotics
  • Meta-analysis
  • Placebo
  • Sleeping pills

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials. / McCall, William Vaughn; D'Agostino, Ralph; Dunn, Aaron.

In: Sleep Medicine, Vol. 4, No. 1, 01.01.2003, p. 57-62.

Research output: Contribution to journalArticle

@article{2834a887d0ed400aa31ddbf53be5fd8f,
title = "A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials",
abstract = "Objectives: The effects associated with placebo (EAP) have been incompletely described in clinical trials of insomnia treatment. We conducted a meta-analysis of insomnia medication trials for the purpose of estimating the magnitude of sleep EAP. Method: We reviewed Medline for 1966 through 2000 for the meta-analysis. The subject heading of insomnia restricted to the subheading of drug therapy was crossed against the results of a search on the subjects heading placebo and text word placebo. We selected only papers that examined primary insomnia, incorporating both placebo and active medication therapies in a randomized, double-blind, parallel-group design. We required that results be reported for 1, 2, 3, or 4 weeks of treatment, and that outcomes be reported in hours/minutes. Results: Five papers satisfied our requirements for eligibility, comprising 213 patients receiving placebo for a 2-week interval. Subjective sleep latency demonstrated a significant reduction (mean ± S.E.) of 13.1 ± 2.0 min (95{\%} confidence interval (CI) 9.2, 17.0) for the placebo group after combining the data across studies. Subjective total sleep time demonstrated a significant increase of 13.5 ± 5.4 min (95{\%} CI 2.9, 24.0). Polysomnographic (PSG) sleep latency demonstrated a non-significant reduction of 2.5 ± 4.3 min (95{\%} CI -5.9, 10.9). Conclusions: The confirmation of EAP in insomnia clinical trials argues for the retention of a placebo control in future insomnia clinical trials.",
keywords = "Ethics, Hypnotics, Meta-analysis, Placebo, Sleeping pills",
author = "McCall, {William Vaughn} and Ralph D'Agostino and Aaron Dunn",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/s1389-9457(02)00242-3",
language = "English (US)",
volume = "4",
pages = "57--62",
journal = "Sleep Medicine",
issn = "1389-9457",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials

AU - McCall, William Vaughn

AU - D'Agostino, Ralph

AU - Dunn, Aaron

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Objectives: The effects associated with placebo (EAP) have been incompletely described in clinical trials of insomnia treatment. We conducted a meta-analysis of insomnia medication trials for the purpose of estimating the magnitude of sleep EAP. Method: We reviewed Medline for 1966 through 2000 for the meta-analysis. The subject heading of insomnia restricted to the subheading of drug therapy was crossed against the results of a search on the subjects heading placebo and text word placebo. We selected only papers that examined primary insomnia, incorporating both placebo and active medication therapies in a randomized, double-blind, parallel-group design. We required that results be reported for 1, 2, 3, or 4 weeks of treatment, and that outcomes be reported in hours/minutes. Results: Five papers satisfied our requirements for eligibility, comprising 213 patients receiving placebo for a 2-week interval. Subjective sleep latency demonstrated a significant reduction (mean ± S.E.) of 13.1 ± 2.0 min (95% confidence interval (CI) 9.2, 17.0) for the placebo group after combining the data across studies. Subjective total sleep time demonstrated a significant increase of 13.5 ± 5.4 min (95% CI 2.9, 24.0). Polysomnographic (PSG) sleep latency demonstrated a non-significant reduction of 2.5 ± 4.3 min (95% CI -5.9, 10.9). Conclusions: The confirmation of EAP in insomnia clinical trials argues for the retention of a placebo control in future insomnia clinical trials.

AB - Objectives: The effects associated with placebo (EAP) have been incompletely described in clinical trials of insomnia treatment. We conducted a meta-analysis of insomnia medication trials for the purpose of estimating the magnitude of sleep EAP. Method: We reviewed Medline for 1966 through 2000 for the meta-analysis. The subject heading of insomnia restricted to the subheading of drug therapy was crossed against the results of a search on the subjects heading placebo and text word placebo. We selected only papers that examined primary insomnia, incorporating both placebo and active medication therapies in a randomized, double-blind, parallel-group design. We required that results be reported for 1, 2, 3, or 4 weeks of treatment, and that outcomes be reported in hours/minutes. Results: Five papers satisfied our requirements for eligibility, comprising 213 patients receiving placebo for a 2-week interval. Subjective sleep latency demonstrated a significant reduction (mean ± S.E.) of 13.1 ± 2.0 min (95% confidence interval (CI) 9.2, 17.0) for the placebo group after combining the data across studies. Subjective total sleep time demonstrated a significant increase of 13.5 ± 5.4 min (95% CI 2.9, 24.0). Polysomnographic (PSG) sleep latency demonstrated a non-significant reduction of 2.5 ± 4.3 min (95% CI -5.9, 10.9). Conclusions: The confirmation of EAP in insomnia clinical trials argues for the retention of a placebo control in future insomnia clinical trials.

KW - Ethics

KW - Hypnotics

KW - Meta-analysis

KW - Placebo

KW - Sleeping pills

UR - http://www.scopus.com/inward/record.url?scp=12244295469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244295469&partnerID=8YFLogxK

U2 - 10.1016/s1389-9457(02)00242-3

DO - 10.1016/s1389-9457(02)00242-3

M3 - Article

C2 - 14592361

AN - SCOPUS:12244295469

VL - 4

SP - 57

EP - 62

JO - Sleep Medicine

JF - Sleep Medicine

SN - 1389-9457

IS - 1

ER -